Contrary to the results regarding HF hospitalizations, SGLT2 inhibitors have notshown a significant decrease in cardiovascular death in any of the majorrandomized clinical trials studying HFpEF patients [14, 18, 19, 36]. This evidence concerns the gene SLC5A2 and hydrops fetalis.